Sunday, October 18, 2015

Subgroup Analyses Show Consistent Benefits of Rivaroxaban (CME/CE)

(MedPage Today) -- Atrial fibrillation patients on new oral anticoagulants fare as well as warfarin-treated patients
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)